Clinical Report: 30 Minutes to Relief? Real-World Data Say Yes

Overview

Hyoscine butylbromide Plus tablets provide rapid and significant relief from menstrual pain, with 91% of patients experiencing a clinically meaningful response within 4 hours, defined as a reduction of at least 30% in NRS score. The study highlights the effectiveness and tolerability of this treatment in a real-world setting.

Background

Dysmenorrhea is a common condition affecting many women, often leading to significant discomfort and impaired quality of life. Effective management is crucial, as many patients remain undertreated despite the availability of therapies. This study evaluates a fixed-dose combination of hyoscine butylbromide and paracetamol, aiming to provide rapid relief for menstrual pain.

Data Highlights

Key Findings

• Median time to first perceptible pain relief was 30 minutes.
• Mean pain intensity reduction was 66% from baseline at 4 hours.
• Patients with severe baseline pain (57%) experienced the greatest percentage reductions.
• 96% of patients reported at least one dysmenorrhea symptom at baseline, decreasing to 70% at 4 hours.
• More than 90% of patients were satisfied with treatment effectiveness.

Clinical Implications

The findings suggest that hyoscine butylbromide Plus is an effective option for rapid relief of menstrual pain, particularly for patients with severe symptoms. Clinicians may consider this combination therapy as part of a management plan for dysmenorrhea, while being aware of the study's limitations, including its observational nature and lack of a comparator group.

Conclusion

This study provides compelling evidence for the rapid efficacy of hyoscine butylbromide Plus in treating menstrual pain, underscoring its potential role in clinical practice. Further research is needed to validate these findings.

References

1. Lange R, et al., Women's Health, 2023 -- A real-world study to describe the effectiveness and usage patterns of hyoscine butylbromide plus tablets in patients with dysmenorrhoea
2. Intensive Care Medicine — A Randomized, Cross-Over, Open-Label Study in the Netherlands Demonstrates That Remifentanil-Propofol Analgo-Sedation Reduces Ventilation Time and ICU Stay Compared to Standard Treatment
3. Clinical Research in Cardiology — Criteria for Assessing Multiple Clinical Outcomes in a Proof-of-Concept Trial: Insights from Pre-RELAX-AHF
4. Open Forum Infectious Diseases — Impact of Healthcare Accessibility on Antibiotic Duration Decisions at Patient Discharge
5. Clinical Research in Cardiology — Gender-Based Variations in Initial Dyspnea Relief Among Hospitalized Patients with Acute Heart Failure: Findings from the RELAX-AHF Study
6. Guideline No. 345: Primary Dysmenorrhea
7. A real-world study to describe the effectiveness and usage patterns of hyoscine butylbromide plus tablets in patients with dysmenorrhoea
8. Frontiers | Heat therapy for primary dysmenorrhea: a systematic review and meta-analysis